Erik van den Berg serves as CEO from 2011 and has over 20 years’ experience in the pharmaceutical and biotechnology industries. Previously he was a Senior Executive at Organon where he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, including a $600M alliance with Pfizer and raised almost €400M in equity and debt financing for biotechnology companies from seed through IPO. Erik is co-founder and board member of Lava Therapeutics and Heatmatrix Group and board member of Lead Pharma, Step Pharma and the Dutch biotechnology organization.
Erik has a Master’s degree in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK), both with distinction.